Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER (PubMed:7876246). Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export (PubMed:11149926).
Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity). Present in the cortical granules of non-activated oocytes, is exocytosed during the cortical reaction in response to oocyte activation and might participate in the block to polyspermy (By similarity)
Monomer. Component of an EIF2 complex at least composed of CELF1/CUGBP1, CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5. Interacts with PDIA3/ERp57 and SPACA9 (By similarity).
Interacts with TRIM21 (PubMed:8666824). Interacts with NR3C1 (PubMed:11149926). Interacts with PPIB (PubMed:20801878).
Interacts (via P-domain) with PDIA5 (PubMed:23614004). Interacts with GABARAP (PubMed:19154346). Interacts with HLA-E-B2M and HLA-G-B2M complexes (PubMed:9427624, PubMed:9640257).
Interacts with HLA-F (PubMed:10605026). Interacts with CLCC1 (PubMed:30157172)
Can be divided into a N-terminal globular domain, a proline-rich P-domain forming an elongated arm-like structure and a C-terminal acidic domain. The P-domain binds one molecule of calcium with high affinity, whereas the acidic C-domain binds multiple calcium ions with low affinity
The interaction with glycans occurs through a binding site in the globular lectin domain
The zinc binding sites are localized to the N-domain
Associates with PDIA3 through the tip of the extended arm formed by the P-domain
| Cancer Type | Mutation Percentage |
|---|---|
| Lung Adenocarcinoma | 0.17% |
| Lung Squamous Cell Carcinoma | 0.68% |
| Pancreas Ductal Carcinoma | 0.08% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to CALR, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 13
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT06034002 | Myeloproliferative Neoplasms | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | PHASE1 | RECRUITING |
| NCT01440413 | Breast Cancer | Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer | NA | UNKNOWN |
| NCT04942080 | Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | NA | RECRUITING |
| NCT04285086 | Essential Thrombocythemia | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | PHASE3 | ACTIVE_NOT_RECRUITING |
| NCT06480591 | Myeloproliferative Neoplasm | Evaluation of the Pathobiology of CALR-mutated MPN Cells | N/A | RECRUITING |
| NCT07008118 | Myeloproliferative Neoplasms | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | PHASE1 | RECRUITING |
| NCT05123326 | Hepatic Vein Thromboses, Hepatic Venous Outflow Obstruction, Portal Vein Thrombosis, Portal Hypertension, Noncirrhotic, Portal Vein Occlusion, Portal Vein Embolism, JAK2 Mutation, CALR Gene Mutation, Prothrombin G20210A, Anticoagulants and Bleeding Disorders | Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome | N/A | UNKNOWN |
| NCT03566446 | Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia, Myelofibrosis | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | PHASE1 | COMPLETED |
| NCT03972943 | CALR Gene Mutation, Essential Thrombocythemia, JAK2 Gene Mutation, MPL Gene Mutation, Obstructive Sleep Apnea Syndrome, Polycythemia Vera | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | EARLY_PHASE1 | TERMINATED |
| NCT05025488 | Myelofibrosis, Essential Thrombocythemia, MPN | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | PHASE1 | RECRUITING |